The EAP space is ever-evolving, and pressures on pharma companies to provide early access to their promising treatments is greater than ever. This brings opportunities and risks that need to be well thought through and planned for.
We have convened a team of leaders in the industry with unrivalled experience in the successful implementation of global EAPs. As a result, we are able to advise and guide our clients in order that a sound strategy can be created and successfully implemented.
Whether you are in very early stages of development or ready to provide access to an investigational treatment during Phase II, Phase III, post-trial or beyond; the Bionical Emas EAP team can provide the solutions.
Global EAP for a specialised Biotech company Play Video
European EAP with tailored RWD strategy Play Video
Global early access program takeover Play Video
- View all